Physician profile
Abdul Hafeez
NPI 1801830716
$2,079.31
in general payments reported to CMS, 2019-2025
21 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $183 · 2021: $459 · 2022: $369 · 2023: $420 · 2024: $149 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $44.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.06 |
| Education | $44.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.98 | 2019-2023 | Lokelma, Farxiga |
| Amgen INC. | $331.30 | 2019-2025 | Krystexxa, Tavneos |
| Nxstage Medical, INC. | $166.47 | 2023 | Nxstage System One, Liberty Select Cycler |
| Horizon Therapeutics Plc | $157.53 | 2020-2023 | Krystexxa |
| Nuwellis, INC. | $149.81 | 2021 | |
| Fresenius USA Marketing, INC. | $91.94 | 2019-2023 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $84.85 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $76.10 | 2025 | |
| Glaxosmithkline, LLC. | $51.63 | 2020-2021 | |
| Daiichi Sankyo INC. | $46.27 | 2021-2022 | |
| Novo Nordisk INC | $34.68 | 2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.20 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $24.89 | 2022 | |
| Lilly USA, LLC | $24.86 | 2025 | Jardiance |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.85 | 2020 | |
| Calliditas Therapeutics US INC. | $22.32 | 2025 | Tarpeyo |
| Recor Medical INC | $22.31 | 2024 | Paradise Renal Denervation System |
| Vifor Pharma, INC. | $21.65 | 2022 | |
| Aurinia Pharma U.S., INC. | $21.45 | 2021 | |
| Abbott Laboratories | $18.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.